Understanding your benefits, verifying coverage, and working with an experienced medical team can significantly improve the approval process and help patients access the treatment they need. Dr
This raises the question as to whether, if there is an effect, the underlying mechanisms do not relate to inhibitory effects on motility, since DPP-4 inhibitors appear to have little to no effect on this parameter in either obese subjects or those with T2D (99)
Lilly reported in ACHIEVE-1 that orforglipron lowered A1C by an average of 1.3% to 1.6% across doses, and the full results were published in The New England Journal of Medicine via PubMed in 2025
Common IF methods include: 16:8 : Fasting for 16 hours and eating within an 8-hour window
As science continues to deliver more powerful solutions for obesity and T2D, the device industrys role will be to ensure these life-changing treatments are accessible, manageable, and acceptable for every patient